Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study

• Status: Completed
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The Ranibizumab in Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration (RIP) Study is a prospective, multicenter, uncontrolled, interventional phase 2 clinical trial that investigates the effect of fixed monthly intravitreal injections of ranibizumab (Lucentis, Novartis Pharma, Germany) on visual acuity and retinal morphology over a study period of 12 months in 30 patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Bonn
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Diagnosis of a pigment epithelial tear secondary to age-related macular degeneration

• Written informed consent

Exclusion Criteria:

• Time of diagnosis more than 6 months before study recruitment

• Ocular surgery of the study eye within 1 month before study recruitment

• Extensive subretinal fibrosis or retinal atrophy of the study eye

• Significant opacification of optical media of the study eye

• Uncontrolled glaucoma of the study eye

• Active ocular inflammation of the study eye

• Best-corrected visual acuity of the contralateral eye below 20/200

• Concurrent ocular or systemic therapy with other vascular endothelial growth factor (VEGF)-inhibitory drugs